Learn more about whether Alvotech or Vericel Corporation is a better investment based on AAII's A+ Investor grades, which ...

Northland Securities analyst Carl Byrnes maintained a Buy rating on Alvotech (ALVO – Research Report) today and set a price target of $28.00.

Learn more about whether Alvotech or Grifols, S.A. is a better investment based on AAII's A+ Investor grades, which compare ...

Alvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities ...

Alvotech (NASDAQ:ALVOW – Get Free Report) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 6,000 shares, a decline of 36.2% from ...

REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025, at 8:00 am ET (12:00pm ...

Alvotech, a biotech firm focused on biosimilar medicine development, announced the acquisition of Xbrane Biopharma’s R&D operations and a biosimilar candidate named XB003, aimed at extending its ...

Good day and thank you for standing by. Welcome to the Alvotech Q4 2024 earnings call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a ...

Revenue: US$492.0m (up 427% from FY 2023). Net loss: US$231.9m (loss narrowed by 58% from FY 2023). US$0.87 loss per share (improved from US$2.43 loss in FY 2023). Revenue exceeded analyst ...

It's been a mediocre week for Alvotech ( NASDAQ:ALVO ) shareholders, with the stock dropping 17% to US$9.55 in the ...

All applications have been subsequently accepted by the relevant regulatory authorities. Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025 ...